iPPI-DB

Inhibitors of Protein-Protein Interaction Database

Compound 231

Identifiers

  • Canonical SMILES: 
    OC(=O)C[C@@H](N1[C@@H](c2ccc(Cl)cc2)C(=O)Nc2ccc(I)cc2C1=O)c1ccc(Cl)cc1
  • IUPAC name: 
    3-(4-chlorophenyl)-3-[3-(4-chlorophenyl)-7-iodo-2,5-dioxo-1,3-dihydro-1,4-benzodiazepin-4-yl]propanoic acid
  • InChi: 
    InChI=1S/C24H17Cl2IN2O4/c25-15-5-1-13(2-6-15)20(12-21(30)31)29-22(14-3-7-16(26)8-4-14)23(32)28-19-10-9-17(27)11-18(19)24(29)33/h1-11,20,22H,12H2,(H,28,32)(H,30,31)/t20-,22+/m1/s1
  • InChiKey: 
    UHDVYHWPJKKLPO-IRLDBZIGSA-N

External links


44176185
CHEMBL379656
23271277

External search

Bibliography (1)

Publication Name
Parks DJ, LaFrance LV, Calvo RR, Milkiewicz KL, Marugán JJ, Raboisson P, Schubert C, Koblish HK, Zhao S, Franks CF, Lattanze J, Carver TE, Cummings MD, Maguire D, Grasberger BL, Maroney AC, Lu T. . Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein-protein interaction through structure-based drug design. Bioorganic & medicinal chemistry letters. 2

Pharmacological data

Biochemical tests Cellular tests PK tests Cytotoxicity tests
1 2 0 0

Targets

PPI family Best activity Diseases MMoA
MDM2-Like / P53 6.27 cancer Inhibition
Physicochemical filters
Descriptor Lipinski's RO5 Veber Pfizer's 3/75
Compliance
MW 593.96 g/mol
HBA 6
HBD 2
HBA + HBD 8
AlogP 6.43
TPSA 86.71
RB 5
Radar chart
PCA : iPPI-DB chemical space
PCA : Correlation circle
Efficiencies: iPPI-DB biplot LE versus LLE
Summary
Bibliographic ressources Biochemical tests Cellular tests PK tests Cytotoxicity tests
1 1 2 0 0
Pharmacological data
Bibliography Name Target Competition Assay type Assay name Cell line Activity type Activity
16600594 2 MDM2
Q00987
Biochemical assay Fluorescence Polarization pIC50 (half maximal inhibitory concentration, -log10) 6.27
16600594 2 MDM2
Q00987
Cellular assay Proliferation assay MCF7 mammary carcinoma cells pIC50 (half maximal inhibitory concentration, -log10) 4.62
16600594 2 MDM2
Q00987
Cellular assay Proliferation assay MDA MB321 mammary carcinoma cells pIC50 (half maximal inhibitory concentration, -log10) 4.15
Ta Structure Name Drugbank ID
0.5476 Bentiromide DB00522
0.5326 Cp403700, (S)-1-{2-[(5-Chloro-1h-Indole-2-Carbonyl)-Amino]-3-Phenyl-Propionyl}-Azetidine-3-Carboxylate DB03744
0.5215 [(2S)-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepin-2-yl]acetic acid DB08717
0.4870 CP-320626 DB03383
0.4847 Iobenzamic acid DB13428
0.4793 [1-(3-CHLORO-2-FORMYL-PHENYLCARBAMOYL)-2-METHYL-PROPYL]-CARBAMIC ACID TERT-BUTYL ESTER DB07956
0.4754 Ombitasvir DB09296
0.4720 4-chloro-N-(3-methoxypropyl)-N-[(3S)-1-(2-phenylethyl)piperidin-3-yl]benzamide DB08344
0.4694 RG-4733 DB11870
0.4683 Oxazolam DB15491
0.4573 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone DB02058
0.4561 (2s)-2-[(2,4-Dichloro-Benzoyl)-(3-Trifluoromethyl-Benzyl)-Amino]-3-Phenyl-Propionic Acid DB03605
0.4546 4-[(4-bromo-2-{[(3R,5S)-3,5-dimethylpiperidin-1-yl]carbonyl}phenyl)amino]-4-oxobutanoic acid DB08581
0.4541 Repaglinide DB00912
0.4535 Fominoben DB08968